Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for OKUR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -10.35M
March 31, 2026 -12.94M
December 31, 2025 -11.51M
September 30, 2025 -13.04M
June 30, 2025 -13.27M
March 31, 2025 -14.00M
December 31, 2024 -21.02M
September 30, 2024 -10.66M
June 30, 2024 -6.473M
March 31, 2024 -10.63M
December 31, 2023 9.383M
September 30, 2023 -18.77M
June 30, 2023 -16.11M
Date Value
March 31, 2023 -9.048M
December 31, 2022 -15.61M
September 30, 2022 -10.79M
June 30, 2022 -11.96M
March 31, 2022 -8.999M
December 31, 2021 -10.02M
September 30, 2021 -9.672M
June 30, 2021 -9.701M
March 31, 2021 -8.589M
December 31, 2020 -5.411M
September 30, 2020 -5.741M
June 30, 2020 -2.937M
March 31, 2020 -4.447M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. 58.28M
Theriva Biologics, Inc. -3.085M
Nkarta, Inc. -24.22M
Unicycive Therapeutics, Inc. -7.604M
ACADIA Pharmaceuticals, Inc. 100.78M